Trigemina Inc., a company developing non-narcotic nasally delivered analgesic drugs, has closed $4.5 million in Series A-1 financing led by existing investor Aurus Bios. Chile-based Aurus made the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback